A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis

Inclusion Criteria: * Male or female subjects aged ≥12\<18 years old, weight ≥ 30kg. * AD diagnosed at least half a year before screening. * Subject with EASI score ≥16, IGA ≥ 3, BSA ≥ 10% at screening and baseline * Daily peak P-NRS scores (weekly average) at baseline visit ≥ 4. Exclusion Criteria: * Acute onset of AD in 4 weeks prior to enrollment. * Undergone or planned surgery during the study period within the 4 weeks prior to enrollment, or unable to fully recover from surgery before enrollment. * Previously suffered from vernal keratoconjunctivitis (VKC) or atopic keratoconjunctivitis (AKC). * Received systemic traditional Chinese medicine treatment within the 4 weeks before randomization or topical traditional Chinese medicine treatment within 1 week before randomization. * Received treatment with other clinical study drugs within 4 weeks or 5 halflives before randomization (whichever is longer). * Have a history of allergies to any component of AK120 and/or severe allergic reactions to monoclonal antibodies.